Progressive metastatic medullary thyroid carcinoma: first- and second-line strategies

    Research output: Contribution to journalReview articlepeer-review

    24 Citations (Scopus)

    Abstract

    The treatment for metastasised medullary thyroid cancer is still a topic of discussion. One of the main challenges remains to find effective adjuvant and palliative options for patients with metastatic disease. The diagnostic and treatment strategies for this tumour are discussed and possible new developments commented. Approaches that target rearranged during transfection (RET) are preferable to those that target RET downstream proteins as, theoretically, blocking RET downstream targets will block only one of the many pathways activated by RET. Combining several agents would seem to be more promising, in particular agents that target RET with those that independently target RET signalling pathways or the more general mechanism of tumour progression.

    Original languageEnglish
    Pages (from-to)R241-R251
    Number of pages11
    JournalEuropean Journal of Endocrinology
    Volume172
    Issue number6
    DOIs
    Publication statusPublished - Jun-2015

    Keywords

    • TYROSINE KINASE INHIBITORS
    • ANTIGEN DOUBLING TIMES
    • PHASE-II TRIAL
    • HISTOLOGIC SUBTYPES
    • PROGNOSTIC-FACTORS
    • RET PROTOONCOGENE
    • CUSHINGS-SYNDROME
    • ENDOCRINE TUMORS
    • CANCER-CELLS
    • IN-VITRO

    Fingerprint

    Dive into the research topics of 'Progressive metastatic medullary thyroid carcinoma: first- and second-line strategies'. Together they form a unique fingerprint.

    Cite this